EMA Addresses Calls To Publish COVID-19 Clinical Data
The European Medicines Agency’s clinical data publication policy is on hold, but calls are growing for the regulator to start publishing trial data for COVID-19 treatments and vaccines as soon as they are authorized in the EU.
You may also be interested in...
The European Medicines Agency says the unprecedented public interest in treatments and vaccines being developed for COVID-19 has highlighted the need to provide access to more information than usual.
In this latest update to coronavirus developments in the EU, the European Medicines Agency outlines plans to monitor demand for medicines in anticipation of a possible second wave of the COVID-19 pandemic later this year. It has also updated its adverse drug reaction literature monitoring service to cover potential coronavirus treatments, and backed the use of ACE-inhibitors and sartans during the pandemic.
The European Medicines Agency has provided an update on the status of its review of Gilead’s investigational antiviral in the treatment of COVID-19.